Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
FRIDAY, DECEMBER 11, 2020
All times are CENTRAL Time
8:30 am  CT WELCOME AND OVERVIEW
Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX
8:45 am - 11:30 am CT

GENERAL SESSION 4

Moderator: Kathy Albain, MD
Loyola University Chicago
Maywood, IL

8:45 am CT GS4-01. Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane
O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, Harbeck N, Wright GS, Bondarenko I, Glaspy J, Nowecki Z, Kayali F, Chan A, Levy C, Liu M-C, Kim S-B, Lemieux J, Manikhas A, Tolaney S, Lim E, Gombos A, Stradella A, Pegram M, Fasching P, Mangel L, Semiglazov V, Dieras V, Gianni L, Danso MA, Vacirca J, Kroll S, O'Connell J, Tang K, Wei T, Seidman A. Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX; West Cancer Center, Memphis, TN; Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium; University of California San Francisco Comprehensive Cancer Center, San Francisco, CA; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN; IOB Institute of Oncology, Quironsalud Group, Madrid and Barcelona, Spain and Vall d´Hebron Institute of Oncology (VHIO), Barcelona, Spain; Helios Hospital Berlin-Buch, Berlin, Germany; Brustzentrum der Universität München (LMU), Munich, Germany; Sarah Cannon Research Institute and Florida Cancer Specialists, New Port Richey, FL; City Clinical Hospital No4, Dnipro, Ukraine; University of California Los Angeles Hematology Oncology Center, Los Angeles, CA; Narodowy Instytut Onkologii-Panstwowy Instytut Badawczy, Warsaw, Poland; Florida Cancer Specialists, Fort Myers, FL; Breast Cancer Research Centre-Western Australia and Curtin University, Perth, Australia; Centre François Baclesse, Caen, France; Koo Foundation Sun Yat‐Sen Cancer Center, Taipei, Taiwan; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; CHU de Québec-Université Laval, Quebec, QC, Canada; City Clinical Oncology Dispensary, St. Petersberg, Russian Federation; Dana-Farber Cancer Institute, Boston, MA; National Cancer Centre, Singapore, Singapore; Institut Catala d'Oncologia Hospital Duran i Reynals, Barcelona, Spain; Stanford Women’s Cancer Center, Palo Alto, CA; Universitätsklinikum Erlangen, Erlangen, Germany; University of Pécs Institute Oncotherapy, Pécs, Hungary; Petrov Research Institute of Oncology, St. Petersburg, Russian Federation; Centre Eugène Marquis, Rennes, France; I.R.C.C.S. Ospedale San Raffaele, Milan, Italy; Virginia Oncology Associates, US Oncology, Norfolk, VA; New York Cancer and Blood Specialists, New York, NY; Odonate Therapeutics, Inc., San Diego, CA; Memorial Sloan Kettering Cancer Center, New York, NY.
9:00 am CT

GS4-02. E2112: randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. a trial of the ecog-acrin cancer research group

Connolly RM, Zhao F, Miller KD, Lee M-J, Piekarz RL, Smith KL, Brown-Glaberman U, Winn JS, Faller BA, Onitilo AA, Burkard ME, Budd GT, Levine EG, Royce ME, Kaufman PA, Thomas A, Trepel JB, Wolff AC, Sparano JA. University College Cork, Cork, Ireland; Dana Farber Cancer Institute, Boston, MA; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN; Trepel Laboratory, National Cancer Institute, Bethesda, MD; Cancer Therapy Evaluation Program, NCI, Bethesda, MD; The Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; University of New Mexico Cancer Center, Albuquerque, NM; Fox Chase Cancer Center, Philadelphia, PA; Heartland NCORP, Missouri Baptist Medical Center, Saint Louis, MO; Marshfield Clinic, Marshfield, WI; University of Wisconsin Carbone Cancer Center, Madison, WI; Cleveland Clinic Foundation, Cleveland, OH; Roswell Park Cancer Institute, Buffalo, NY; New Mexico MU-NCORP, Albuquerque, NM; University of Vermont Cancer Center, Burlington, VT; Wake Forest University, Winston Salem, NC; Trepel Laboratory, NCI, Bethesda, MD; Johns Hopkins University, Baltimore, MD; Montefiore Medical Center, Bronx, NY.
9:15 am CT

GS4-03. Neoadjuvant nab-paclitaxel weekly versus dose-dense paclitaxel followed by dose-dense EC in high risk HR+/HER2- early BC by: results from the neoadjuvant part of ADAPT HR+/HER2- trial

Kuemmel S, Gluz O, Nitz U, Braun M, Christgen M, Luedtke-Heckenkamp K, von Schumann R, Darsow M, Forstbauer H, Potenberg J, Grischke E-M, Aktas B, Schumacher C, Kates R, Graeser M, Wuerstlein R, Uleer C, Hauptmann M, Shak S, Baehner R, Kreipe H, Harbeck N, West German Study Group. Breast Unit, Clinics Essen-Mitte, Essen and West German Study Group, Essen, Germany; Breast Center Niederrhein, Johanniter Bethesda Moenchengladbach and West German Study Group and University of Cologne, Moenchengaldbach, Germany; Breast Center Niederrhein, Johanniter Bethesda Moenchengladbach and West German Study Group, Moenchengladbach, Germany; Clinics Rotkreuz, Breast Center, Munich, Germany; Medical College of Hannover, Institute for Pathology, Hannover, Germany; Niels Stensen Clinics, Clinics for Oncology, Osnabrueck, Germany; Breast Center Niederrhein, Johanniter Bethesda Moenchengladbach, Moenchengladbach, Germany; Luisenhospital Duesseldorf, Practice for Senologic Oncology, Duesseldorf, Germany; Oncology Practice Network Troisdorf, Troisdorf, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; University Clinics Tübingen, Women’s Clinic, Tuebingen, Germany; University Clinics Leipzig, Women’s Clinic, Leipzig, Germany; St. Elisabeth Hospital, Cologne, Germany; West German Study Group, Moenchengladbach, Germany; Breast Center, Dept. OB&GYN and CCCLMU, LMU University Hospital, Munich, Germany; Gynecologists at Bahnhofsplatz, Hildesheim, Germany; Brandenburg Medical School Theodor Fontane, Neuruppin, Germany; Genomic Health, Inc., Redwood City, CA.
9:30 am CT

GS4-04. Endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), Recurrence Score <26 and Ki67 response after preoperative endocrine therapy: First efficacy results from the ADAPT HR+/HER2- trial (n=4,690)

Harbeck N, Gluz O, Kuemmel S, Christgen M, Braun M, Aktas B, Luedtke-Heckenkamp K, Forstbauer H, Grischke E-M, Schumacher C, Darsow M, Krauss K, Nuding B, Thill M, Potenberg J, Uleer C, Warm M, Fischer HH, Malter W, Hauptmann M, Kates R, Graeser M, Wuerstlein R, Shak S, Baehner R, Kreipe H, Nitz U, West German Study Group. Breast Center, Dept. OB&GYN and CCCLMU, LMU University Hospital, Munich, Germany; Breast Center Niederrhein, Johanniter Bethesda Moenchengladbach and West German Study Group and University of Cologne, Moenchengaldbach, Germany; Breast Unit, Clinics Essen-Mitte, Essen and West German Study Group, Essen, Germany; Medical College of Hannover, Institute for Pathology, Hannover, Germany; Clinics Rotkreuz, Breast Center, Munich, Germany; University Clinics Leipzig, Women’s Clinic, Leipzig, Germany; Niels Stensen Clinics, Clinics for Oncology, Osnabrueck, Germany; Oncology Practice Network Troisdorf, Troisdorf, Germany; University Clinics Tübingen, Women’s Clinic, Tuebingen, Germany; St. Elisabeth Hospital, Cologne, Germany; Luisenhospital Duesseldorf, Practice for Senologic Oncology, Duesseldorf, Germany; University Clinics Aachen, Women’s Clinic, Aachen, Germany; Ev. Hospital Bergisch Gladbach, Bergisch Gladbach, Germany; Agaplesion Markus Hospital, Breast Center, Frankfurt, Germany; Ev. Waldkrankenhaus Berlin, Berlin, Germany; Gynecologists at Bahnhofsplatz, Hildesheim, Germany; City Hospital Holweide, Breast Center, Cologne, Germany; Evangelische Kliniken, Gelsenkirchen, Germany; University Clinics Cologne, Women’s Clinic and Breast Center, Cologne, Germany; Brandenburg Medical School Theodor Fontane, Neuruppin, Germany; West German Study Group, Moenchengladbach, Germany; Breast Center Niederrhein, Johanniter Bethesda Moenchengladbach and West German Study Group, Moenchengladbach, Germany; Genomic Health, Inc., Redwood City, CA
9:45 am CT GS4-05. Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)
Ma CX, Suman V, Leitch AM, Sanati S, Vij K, Unzeitig GW, Hoog J, Watson M, Hahn O, Guenther J, Caudle A, Crouch E, Maluf H, Tiersten A, Mita M, Razaq W, THieken TJ, Wang Y, Dockter T, Zujewski JA, Weiss A, Hunt K, Hudis C, Winer EP, Ellis MJ, Carey LA, Partridge AH. Washington University School of Medicine, St. Louis, MO; Alliance Statistics and Data Center, Rochester, MN; University of Texas Southwestern Medical Center, Dallas, TX; Cedars-Sinai Medical Center, Los Angelos, CA; Doctor's Hospital of Laredo, Laredo, TX; University of Chicago, Chicago, IL; Saint Elizabeth Medical Center South, Edgewood, KY; MD Anderson Cancer Center, Houston, TX; Mount Sinai Hospital, New York, NY; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Mayo Clinic, Rochester, MN; Presbyterian Kaseman Hospital, Albuquerque, NM; National Cancer Institute, Bethesda, MD; Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Baylor College of Medicine, Houston, TX; University of North Carolina, Chapel Hill, NC.
10:00 am CT GS4-06 Discussant
Lajos Pusztai, MD, PhD
Yale University
New Haven, CT
10:15 am CT

GS4-07. Assessing prognosis after neoadjuvant therapy: A comparison between anatomic ypAJCC staging, Residual Cancer Burden Class and Neo-Bioscore

van der Noordaa MEM, Yau C, Shad S, Osdoit M, Steenbruggen TG, de Croze D, Hamy A-S, Lae M, Reyal F, Del Monte-Millán M, Martin M, Lopez Tarruella S, I-SPY 2 TRIAL Consortium, Boughey JC, Goetz M, Hoskin T, Gould R, Valero V, Sonke G, van Seijen M, Wesseling J, Bartlett J, Edge S, Kim M-O, Abraham J, Caldas C, Earl H, Provenzano E, Sammut S-J, Cameron D, Graham A, Hall P, MacKintosh L, Fan F, Godwin AK, Schwensen K, Sharma P, DeMichele A, Dunn J, Hiller L, Hayward L, Thomas J, Cole K, Pusztai L, van 't Veer L, Symmans F, Esserman L. University of California, San Francisco, San Francisco, CA; Institut Curie, Paris, France; Netherlands Cancer Institute, Amsterdam, Netherlands; Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain; Mayo Clinic, Rochester, MN; MD Anderson Cancer Center, Houston, TX; Ontario Institute for Cancer Research, Toronto, ON, Canada; Roswell Park Comprehensive Cancer Center, Buffalo, NY; University of Cambridge, Cambridge, United Kingdom; University of Edinburgh, Edinburgh, United Kingdom; University of Kansas, Kansas City, KS; University of Pennsylvania, Pennsylvania, PA; University of Warwick, Coventry, United Kingdom; Western General Hospital, Edinburgh, United Kingdom; Yale University, New Haven, CT.
10:30 am CT GS4-08. Clinical utility of repeated circulating tumor cell (CTC) enumeration as early treatment monitoring tool in metastatic breast cancer (MBC) - a global pooled analysis with individual patient data
Janni W, Yab TC, Hayes DF, Cristofanilli M, Bidard F-C, Ignatiadis M, Regan MM, Alix-Panabières C, Barlow WE, Caldas C, Carey LA, Dirix L, Fehm T, Garcia-Saenz JA, Gazzaniga P, Generali D, Gerratana L, Gisbert-Criado R, Jacot W, Jiang Z, Lianidou E, Magbanua MJM, Manso L, Mavroudis D, Müller V, Munzone E, Pantel K, Pierga J-Y, Rack B, Riethdorf S, Rugo HS, Sideras K, Sleijfer S, Smerage J, Stebbing J, Terstappen LWMM, Vidal-Martínez J, Zamarchi R, Giridhar K, Friedl TWP, Liu MC. Department of Obstetrics and Gynecology, University Hospital Ulm, Ulm, Germany; Department of Oncology, Mayo Clinic, Rochester, MN; Breast Oncology Program, University of Michigan Rogel Cancer Center, Ann Arbor, MI; Department of Medicine, Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL; Department of Medical Oncology, Institute Curie, UVSQ University, Paris & St Cloud, FranceDepartment of Medical Oncology, Institute Jules Bordet, Université Libre de Bruxelles, Brussels, BelgiumDivision of Biostatistics, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA; Laboratory of Rare Human Circulating Cells (LCCRH), University Medical Centre of Montpellier, Montpellier, FranceSWOG Statistical Center, Seattle, WA; Department of Oncology, Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United KingdomDivision of Hematology-Oncology, University of North Carolina, Chapel Hill, NC; University of Antwerp and GZA Sint-Augustinus, Antwerp, BelgiumDepartment of Gynecology and Obstetrics, Heinrich Heine University Düsseldorf, Düsseldorf, GermanyDCIBERONC, IdISCC Madrid, Madrid, SpainDepartment of Molecular Medicine, Sapienza University of Rome, Rome, ItalyWomen Cancer Center, Azienda Socio Sanitaria Territoriale di Cremona, University of Trieste, Trieste, ItalyDepartment of Medicine (DAME) - The University of Udine, Udine, ItalyClinical Laboratory, Hospital Arnau de Vilanova, Valencia, SpainDepartment of Medical Oncology, Institut du Cancer de Montpellier (ICM), IRCM, INSERM U1194, Université de Montpellier, Montpellier, FranceDepartment of Breast Cancer, The 307th Hospital of Chinese People’s Liberation Army, Beijing, ChinaLaboratory of Analytical Chemistry, Analysis of Circulating Tumor Cells (ACTC) Lab, Department of Chemistry, University of Athens, Athens, GreeceUniversity of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, SpainDepartment of Medical Oncology, University General Hospital of Heraklion, Heraklion, GreeceDepartment of Gynecology and Obstetrics, University Hospital Hamburg-Eppendorf, Hamburg, GermanyDivision of Medical Senology, European Institute of Oncology, IRCCS, Milan, ItalyDepartment of Tumor Biology, University Medical Center Hamburg-Eppendorf, Hamburg, GermanyDepartment of Medical Oncology, Institute Curie, Paris & St Cloud, Paris University, Paris, FranceHematology and Medical Oncology, Mayo Clinic, Jacksonville, FL; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, NetherlandsDivision of Cancer, Department of Surgery and Cancer, Imperial College London, London, United KingdomMedical Cell BioPhysics Group, MIRA Institute, Faculty of Science and Technology, University of Twente, Enschede, NetherlandsVeneto Institute of Oncology IOV-IRCCS, Padua, Italy.
10:45 am CT

GS4-09. Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study

Sgroi DC, Treuner K, Zhang Y, Piper T, Salunga R, Ahmed I, Doos L, Thornber S, Taylor KJ, Brachtel EF, Pirrie S, Schnabel CA, Rea DW, Bartlett JMS. Massachusetts General Hospital, Boston, MA; Biotheranostics, Inc., San Diego, CA; University of Edinburgh, Edinburgh, United Kingdom; University of Birmingham, Cancer Research UK Clinical Trails Unit, Birmingham, United Kingdom; Ontario Institute of Cancer Research, Ontario, ON, Canada.
11:00 am CT GS4-10. Development and validation of a tool integrating the 21-gene recurrence score and clinicopathlogic features to individualize prognosis for distant recurrence and prediction of absolute chemotherapy benefit in early breast cancer
Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY; Exact Sciences, Redwood City, CA; University of Pittsburgh, NRG Statistics and Data Management Center, Pittsburgh, PA; ECOG-ACRIN Statistical Center, Dana Farber Cancer Institute, Boston, MA; Davidoff Center, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv, Israel.
11:15 am CT GS4-11. How low is low risk: MINDACT updated outcome and treatment benefit in patients considered clinical low risk and stratified by genomic signature, age and nodal status
  van 't Veer LJ, Cardoso F, Poncet C, Lopes Cardozo J, Delaloge S, Pierga J-Y, Vuylsteke P, Brain E, Viale G, Kümmel S, Rubio IT, Zoppoli G, Thompson A, Matos E, Zaman K, Knox S, Hilbers F, Peric A, Meulemans B, Picccart M, Rutgers EJTh. Univ California San Francisco, San Francisco, CA; Champalimaud Clinical Center/Champalimaud Foundation, Lisbon, Portugal; EORTC Headquarters, Brussels, Belgium; Gustave Roussy, Villejuif, France; Institut Curie, Paris, France; CHU Site Sainte-Elisabeth-UCL Namur, Namur, Belgium; Institut Curie - Hôpital Rene Huguenin, Saint-Cloud, France; University of Milan & IEO, European Institute of Oncology IRCCS, Milan, Italy; Breast Unit, Kliniken Essen-Mitte, Essen, Germany; Clinica Universidad de Navarra, Madrid, Spain; University of Genoa & Azienda Ospedaliera, Genova, Italy; Baylor College of Medicine, Houston, TX; Institute of Oncology, Ljubljan, Slovenia; University Hospital CHUV, Lausanne, Switzerland; Europa Donna-European Breast Cancer Coalition, Milan, Italy; Breast International Group Headquarters, Brussels, Belgium; Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, Netherlands.
   
10:00 am - 3:00 pm CT EXHIBITS
11:30 am - 12:30 pm CT DEBATE

All Breast Cancer Patients Should Have Germline Genetic Testing
Moderator: Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

For
Mark Robson, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Against
Susan Domchek, MD
University of Pennsylvania
Philadelphia, PA

12:30 pm - 1:00 pm CT BREAK
1:00 pm - 2:15 pm CT

SPOTLIGHT SESSION 10 - Hereditary Predisposition

  Chair: Anna C. Weiss, MD
Brigham and Women's Health
Boston, MA

            Jennifer Litton, MD
            UT MD Anderson Cancer Center
            Houston, TX

            Ephrat Levy-Lahad, MD
            Shaare Zedek Medical Center
            Jerusalem, Israel

            Rita Schmutzler
            Center for Familial Breast- and Ovarian Cancer
            Cologne, Germany

   
1:00 pm - 2:15 pm CT SPOTLIGHT SESSION 13 - Brain Metastases Targets and Treatment
 

Chair: Andrew Brenner, MD
UT Health San Antonio
San Antonio, TX

Target, sanctuary site
Priscilla K. Brastianos, MD
Massachusetts General Hospital
Boston, MA  

Therapies
Carey Anders, MD
Duke University
Durham, NC     

   
2:15 pm - 3:30 pm CT SPOTLIGHT SESSION 11 - Novel Strategies for Breast Cancer Prevention: Diet, Exercise and Vaccine
 

Chair: Katherine Crew, MD, MSc
Columbia University Irving Medical Center
New York, NY

Preventing breast cancer through energy balance interventions 
Neil Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York

Novel cancer prevention interventions 
Andrea DeCensi, MD
E.0. Ospedali Galliera
Genoa, Italy 

   
2:15 pm - 3:30 pm CT SPOTLIGHT SESSION 14 - Immune Biomarkers and Immune Oncology
 

Chair: Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Cancer Institute
Brigham and Women's Cancer Center
Boston, MA

Immune biomarkers
Sandra Demaria, MD
Weill Cornell Medicine
New York, NY

Immune oncology
Sangeetha Reddy, MD
UT Southwestern Medical Center
Dallas, TX

   
3:30 pm - 4:45 pm CT

SPOTLIGHT SESSION 12 - Chronic Health Conditions and Quality of Life in Breast Cancer Survivorship

 

Chair: Jennifer Klemp, PhD, MPH
Back in the Swing USA
Leawood, KS 

Chronic stress, sleep deprivation and health implications on breast cancer survivors
Tara Sanft, MD
Yale University School of Medicine
New Haven, CT

CVAs, infertility and gynecologic complications: what else is affecting the patient?
Anne Blaes, MD, MS
University of Minnesota
Minneapolis, MN

Quality of life and support in breast cancer care
Michelle Melisko, MD
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA 

   
3:30 pm - 4:45 pm CT SPOTLIGHT SESSION 15 - Triple Negative Breast Cancer: Metabolism and Metastasis
 

Chair: Stacy Moulder, MD
UT MD Anderson Cancer Center
Houston, TX

Metastasis
Heide L. Ford, PhD
University of Colorado Anschutz Medical Campus
Aurora, CO

Metabolism
Brian D. Lehmann, PhD
Vanderbilt University School of Medicine
Nashville, TN

   
5:00 pm - 7:00 pm CT SPECIAL SESSION
View from the Trenches: What Will You Do On Monday Morning?
Moderator: Steven Vogl MD
Bronx, NY

Panel Members:

Peter Dubsky, MD, PhD
Hirslanden Klinik St Anna, Breast Centre
Lucern Switzerland

William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center
Chicago, IL

Alice Ho, MD, MBA
Massachusetts General Hospital
Boston, MA

Sara A. Hurvitz, MD, FACP
University of California, Los Angeles
Jonsson Comprehensive Cancer Center
Santa Monica, CA

Valencia Robinson
Patient Advocate
Daytona Beach, FL

Martine J. Piccart-Gebhart, MD, PhD
Institut Jules Bordet
Brussels, Belgium

Meredith Regan, SCD
Dana-Farber Cancer Institute
Boston, MA

7:00 pm CT The Year in Review
Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

Basic science
Helen Piwnica-Worms, PhD
UT MD Anderson Cancer Center
Houston, TX

Translational research
Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

Early breast cancer
Erika Hamilton, MD
Sara Cannon Research Institute
Nashville, TN

Advanced breast cancer
Rebecca Dent, MD, MSc
National Cancer Center Singapore
Duke-NUS Medical School
Singapore
7:30 pm CT OPEN SATELLITE EVENT presented by Research to Practice

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Patients with Triple-Negative Breast Cancer — Part 2 of a 2-Part CME Satellite Symposia Series

For more information and to register for this event, please click on the link below:
http://www.researchtopractice.com/Meetings/SA2020


Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
In collaboration with  Astro     and     SSO